Literature DB >> 3565227

Fibrinogen, cigarette smoking, and risk of cardiovascular disease: insights from the Framingham Study.

W B Kannel, R B D'Agostino, A J Belanger.   

Abstract

During the tenth biennial examination, 1315 Framingham study participants free of cardiovascular disease had fibrinogen measured along with other major cardiovascular risk factors including cigarette smoking. The fibrinogen values were significantly higher in smokers than in nonsmokers, increased with the amount smoked in each sex, and exsmokers had values as low as those of nonsmokers. Over 10 years of follow-up, 165 men and 147 women developed cardiovascular disease, the risk in both sexes increasing progressively in relation to antecedent fibrinogen values over the 180 to 450 mg/dl range. Risk gradients for cardiovascular disease in men diminished with advancing age. In men, risk of cardiovascular disease was related to cigarette smoking. This was true in the multivariate case taking all standard risk factors into account. As for fibrinogen, the impact diminished with advancing age. Regression coefficients were actually larger in the multivariate than in the univariate case because of a negative correlation between smoking and blood pressure. Fibrinogen contributed to cardiovascular disease, risk taking into account both cigarette smoking and other risk factors. When fibrinogen is added to the multivariate model for prediction of cardiovascular disease the coefficient for smoking becomes much reduced and is no longer statistically significant. However, each independently contributed to risk in cross-sectional analysis. These data provide another mechanism whereby cigarette smoking influences the occurrence of atherocardiovascular disease and also another reason for prohibiting cigarette use.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3565227     DOI: 10.1016/0002-8703(87)90063-9

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  60 in total

1.  Acute Coronary Syndromes: Molecular Basis for Cardiac Risk Factors.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1997       Impact factor: 2.300

2.  Lipid profile, haemostatic variables and angiographically-defined coronary artery disease: a cross-sectional study in an Irish population.

Authors:  J Galvin; M Codd; S Leavy; D Sugrue
Journal:  Ir J Med Sci       Date:  1996 Apr-Jun       Impact factor: 1.568

3.  Stimulation of fibrinogen synthesis in cultured rat hepatocytes by fibrinogen degradation product fragment D.

Authors:  F M LaDuca; L A Tinsley; C V Dang; W R Bell
Journal:  Proc Natl Acad Sci U S A       Date:  1989-11       Impact factor: 11.205

4.  Smoking, smoking cessation, and risk of cardiovascular disease.

Authors:  Peter W F Wilson
Journal:  Curr Treat Options Cardiovasc Med       Date:  2006-08

5.  The smoker's paradox and the real risk of smoking.

Authors:  Friedebert Kunz; Christoph Pechlaner; Helmut Hörtnagl; Rudolf Pfister
Journal:  Eur J Epidemiol       Date:  2005       Impact factor: 8.082

Review 6.  Hemophilia treatment in historical perspective: a review of medical and social developments.

Authors:  F R Rosendaal; C Smit; E Briët
Journal:  Ann Hematol       Date:  1991-02       Impact factor: 3.673

7.  Smoking and red blood cell phospholipid membrane fatty acids.

Authors:  H J Murff; H A Tindle; M J Shrubsole; Q Cai; W Smalley; G L Milne; L L Swift; R M Ness; W Zheng
Journal:  Prostaglandins Leukot Essent Fatty Acids       Date:  2016-08-16       Impact factor: 4.006

8.  Hyperfibrinogenemia and functional outcome from acute ischemic stroke.

Authors:  Gregory J del Zoppo; David E Levy; Warren W Wasiewski; Arthur M Pancioli; Andrew M Demchuk; James Trammel; Bart M Demaerschalk; Markku Kaste; Gregory W Albers; Eric B Ringelstein
Journal:  Stroke       Date:  2009-03-19       Impact factor: 7.914

9.  Fibrinogen beta-chain tyrosine nitration is a prothrombotic risk factor.

Authors:  Ioannis Parastatidis; Leonor Thomson; Anne Burke; Irina Chernysh; Chandrasekaran Nagaswami; Jetze Visser; Sheryl Stamer; Daniel C Liebler; George Koliakos; Harry F G Heijnen; Garret A Fitzgerald; John W Weisel; Harry Ischiropoulos
Journal:  J Biol Chem       Date:  2008-09-25       Impact factor: 5.157

Review 10.  The benefits of stopping smoking and the role of nicotine replacement therapy in older patients.

Authors:  S G Gourlay; N L Benowitz
Journal:  Drugs Aging       Date:  1996-07       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.